Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure
We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer. Prostate-specific antigen (PSA) failure-free survival was assessed according to two different d...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2006-10, Vol.11 (5), p.396-402 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 402 |
|---|---|
| container_issue | 5 |
| container_start_page | 396 |
| container_title | International journal of clinical oncology |
| container_volume | 11 |
| creator | Mitsumori, Michihide Sasaki, Yoshihide Mizowaki, Takashi Takayama, Kenji Nagata, Yasushi Hiraoka, Masahiro Negoro, Yoshiharu Sasai, Keisuke Kinoshita, Hidefumi Kamoto, Toshiyuki Ogawa, Osamu |
| description | We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer. Prostate-specific antigen (PSA) failure-free survival was assessed according to two different definitions, and the appropriateness of each definition is discussed.
Between October 1997 and December 2000, 27 patients with stage III prostate cancer were enrolled in this study. The median pretreatment PSA level was 29 ng/ml (range, 7.4-430 ng/ml). The Gleason score (GS) was 7 or more in 22 patients (81%). All patients received 3 months of NHT with a luteinizing hormone-releasing hormone (LH-RH) analogue, in combination with an antiandrogen (flutamide), given during the first 2 weeks, followed by 70-Gy external-beam radiation therapy (EBRT) in 35 fractions. The initial 46 Gy was given with a four-field technique, while the remainder was given with a dynamic conformal technique. No adjuvant hormonal therapy (AHT) was given.
The median follow-up time was 63 months. PSA levels decreased to the normal range ( |
| doi_str_mv | 10.1007/s10147-006-0600-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68981003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68981003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c294t-9f1e7c3dd030848fefc553ca453772cc20d6b65ad0849a1f83ff1e80517e05e53</originalsourceid><addsrcrecordid>eNpdUU1v3CAQRVWj5qs_oJcK9ZCbm8EYY_cWRUmzUqREaXNGLAxdVrbZAm6UH5P_Wra7aqScGDTvvZl5j5BPDL4yAHmeGLBGVgBtBS1AJd-RI9ZwWUkp6_el5g2r-rYWh-Q4pTUAk62oP5BDJkF0jHdH5OUB0zzkRIOjUVuvsw8TzSuMevNMTRiXfkJLn3xe0QmDtuv5j54yXYU4hkkP_6EuRJqy_oV0sVjQTQzlk5EaPRmM37ZKGx19KuJlUn4K1HrnMGLRsuj85LeD_61x_-OCOu2HOeIpOXB6SPhx_56Qx-urn5c31e3d98XlxW1l6r7JVe8YSsOtBQ5d0zl0RghudCN4McKYGmy7bIW2pdtr5jruCqMDwSSCQMFPyNlOt-z9e8aU1eiTwWHQ5eY5qbbru-I4L8Avb4DrMMfiQ1I18J7zmkEBsR3IFBdSRKc20Y86PisGahuc2gWnSnBqG5yShfN5LzwvR7SvjH1S_C-HaJZC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>203933210</pqid></control><display><type>article</type><title>Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Mitsumori, Michihide ; Sasaki, Yoshihide ; Mizowaki, Takashi ; Takayama, Kenji ; Nagata, Yasushi ; Hiraoka, Masahiro ; Negoro, Yoshiharu ; Sasai, Keisuke ; Kinoshita, Hidefumi ; Kamoto, Toshiyuki ; Ogawa, Osamu</creator><creatorcontrib>Mitsumori, Michihide ; Sasaki, Yoshihide ; Mizowaki, Takashi ; Takayama, Kenji ; Nagata, Yasushi ; Hiraoka, Masahiro ; Negoro, Yoshiharu ; Sasai, Keisuke ; Kinoshita, Hidefumi ; Kamoto, Toshiyuki ; Ogawa, Osamu</creatorcontrib><description>We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer. Prostate-specific antigen (PSA) failure-free survival was assessed according to two different definitions, and the appropriateness of each definition is discussed.
Between October 1997 and December 2000, 27 patients with stage III prostate cancer were enrolled in this study. The median pretreatment PSA level was 29 ng/ml (range, 7.4-430 ng/ml). The Gleason score (GS) was 7 or more in 22 patients (81%). All patients received 3 months of NHT with a luteinizing hormone-releasing hormone (LH-RH) analogue, in combination with an antiandrogen (flutamide), given during the first 2 weeks, followed by 70-Gy external-beam radiation therapy (EBRT) in 35 fractions. The initial 46 Gy was given with a four-field technique, while the remainder was given with a dynamic conformal technique. No adjuvant hormonal therapy (AHT) was given.
The median follow-up time was 63 months. PSA levels decreased to the normal range (<4 ng/ml) after irradiation in all but one patient. The 5-year PSA failure-free survival was 34.8% according to the American Society for Therapeutic Radiology and Oncology (ASTRO) definition and it was 43.0% according to the "nadir plus 2" definition. Discordance of the results between the two definitions was seen in two patients. The 5-year overall and cause-specific survivals were 83.0% and 93.3%, respectively. No severe acute or late adverse effects were observed.
Seventy Gy of EBRT following 3 months of NHT produced therapeutic results comparable to those reported in other studies which used long-term AHT. The value of long-term AHT for Japanese men should be tested in a clinical trial.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-006-0600-7</identifier><identifier>PMID: 17058138</identifier><language>eng</language><publisher>Japan: Springer Nature B.V</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - immunology ; Adenocarcinoma - pathology ; Adenocarcinoma - radiotherapy ; Aged ; Androgen Antagonists - therapeutic use ; Biomarkers, Tumor - blood ; Clinical outcomes ; Clinical trials ; Cohort Studies ; Comparative studies ; Drug Therapy, Combination ; Flutamide - therapeutic use ; Gonadotropin-Releasing Hormone - therapeutic use ; Hormones ; Humans ; Japan ; Male ; Middle Aged ; Neoadjuvant Therapy - methods ; Neoplasm Staging ; Oncology ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - immunology ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Radiation ; Radiotherapy Dosage ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Analysis</subject><ispartof>International journal of clinical oncology, 2006-10, Vol.11 (5), p.396-402</ispartof><rights>The Japan Society of Clinical Oncology 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c294t-9f1e7c3dd030848fefc553ca453772cc20d6b65ad0849a1f83ff1e80517e05e53</citedby><cites>FETCH-LOGICAL-c294t-9f1e7c3dd030848fefc553ca453772cc20d6b65ad0849a1f83ff1e80517e05e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17058138$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mitsumori, Michihide</creatorcontrib><creatorcontrib>Sasaki, Yoshihide</creatorcontrib><creatorcontrib>Mizowaki, Takashi</creatorcontrib><creatorcontrib>Takayama, Kenji</creatorcontrib><creatorcontrib>Nagata, Yasushi</creatorcontrib><creatorcontrib>Hiraoka, Masahiro</creatorcontrib><creatorcontrib>Negoro, Yoshiharu</creatorcontrib><creatorcontrib>Sasai, Keisuke</creatorcontrib><creatorcontrib>Kinoshita, Hidefumi</creatorcontrib><creatorcontrib>Kamoto, Toshiyuki</creatorcontrib><creatorcontrib>Ogawa, Osamu</creatorcontrib><title>Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><description>We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer. Prostate-specific antigen (PSA) failure-free survival was assessed according to two different definitions, and the appropriateness of each definition is discussed.
Between October 1997 and December 2000, 27 patients with stage III prostate cancer were enrolled in this study. The median pretreatment PSA level was 29 ng/ml (range, 7.4-430 ng/ml). The Gleason score (GS) was 7 or more in 22 patients (81%). All patients received 3 months of NHT with a luteinizing hormone-releasing hormone (LH-RH) analogue, in combination with an antiandrogen (flutamide), given during the first 2 weeks, followed by 70-Gy external-beam radiation therapy (EBRT) in 35 fractions. The initial 46 Gy was given with a four-field technique, while the remainder was given with a dynamic conformal technique. No adjuvant hormonal therapy (AHT) was given.
The median follow-up time was 63 months. PSA levels decreased to the normal range (<4 ng/ml) after irradiation in all but one patient. The 5-year PSA failure-free survival was 34.8% according to the American Society for Therapeutic Radiology and Oncology (ASTRO) definition and it was 43.0% according to the "nadir plus 2" definition. Discordance of the results between the two definitions was seen in two patients. The 5-year overall and cause-specific survivals were 83.0% and 93.3%, respectively. No severe acute or late adverse effects were observed.
Seventy Gy of EBRT following 3 months of NHT produced therapeutic results comparable to those reported in other studies which used long-term AHT. The value of long-term AHT for Japanese men should be tested in a clinical trial.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Biomarkers, Tumor - blood</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Cohort Studies</subject><subject>Comparative studies</subject><subject>Drug Therapy, Combination</subject><subject>Flutamide - therapeutic use</subject><subject>Gonadotropin-Releasing Hormone - therapeutic use</subject><subject>Hormones</subject><subject>Humans</subject><subject>Japan</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - immunology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiation</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUU1v3CAQRVWj5qs_oJcK9ZCbm8EYY_cWRUmzUqREaXNGLAxdVrbZAm6UH5P_Wra7aqScGDTvvZl5j5BPDL4yAHmeGLBGVgBtBS1AJd-RI9ZwWUkp6_el5g2r-rYWh-Q4pTUAk62oP5BDJkF0jHdH5OUB0zzkRIOjUVuvsw8TzSuMevNMTRiXfkJLn3xe0QmDtuv5j54yXYU4hkkP_6EuRJqy_oV0sVjQTQzlk5EaPRmM37ZKGx19KuJlUn4K1HrnMGLRsuj85LeD_61x_-OCOu2HOeIpOXB6SPhx_56Qx-urn5c31e3d98XlxW1l6r7JVe8YSsOtBQ5d0zl0RghudCN4McKYGmy7bIW2pdtr5jruCqMDwSSCQMFPyNlOt-z9e8aU1eiTwWHQ5eY5qbbru-I4L8Avb4DrMMfiQ1I18J7zmkEBsR3IFBdSRKc20Y86PisGahuc2gWnSnBqG5yShfN5LzwvR7SvjH1S_C-HaJZC</recordid><startdate>200610</startdate><enddate>200610</enddate><creator>Mitsumori, Michihide</creator><creator>Sasaki, Yoshihide</creator><creator>Mizowaki, Takashi</creator><creator>Takayama, Kenji</creator><creator>Nagata, Yasushi</creator><creator>Hiraoka, Masahiro</creator><creator>Negoro, Yoshiharu</creator><creator>Sasai, Keisuke</creator><creator>Kinoshita, Hidefumi</creator><creator>Kamoto, Toshiyuki</creator><creator>Ogawa, Osamu</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200610</creationdate><title>Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure</title><author>Mitsumori, Michihide ; Sasaki, Yoshihide ; Mizowaki, Takashi ; Takayama, Kenji ; Nagata, Yasushi ; Hiraoka, Masahiro ; Negoro, Yoshiharu ; Sasai, Keisuke ; Kinoshita, Hidefumi ; Kamoto, Toshiyuki ; Ogawa, Osamu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c294t-9f1e7c3dd030848fefc553ca453772cc20d6b65ad0849a1f83ff1e80517e05e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Biomarkers, Tumor - blood</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Cohort Studies</topic><topic>Comparative studies</topic><topic>Drug Therapy, Combination</topic><topic>Flutamide - therapeutic use</topic><topic>Gonadotropin-Releasing Hormone - therapeutic use</topic><topic>Hormones</topic><topic>Humans</topic><topic>Japan</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - immunology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiation</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mitsumori, Michihide</creatorcontrib><creatorcontrib>Sasaki, Yoshihide</creatorcontrib><creatorcontrib>Mizowaki, Takashi</creatorcontrib><creatorcontrib>Takayama, Kenji</creatorcontrib><creatorcontrib>Nagata, Yasushi</creatorcontrib><creatorcontrib>Hiraoka, Masahiro</creatorcontrib><creatorcontrib>Negoro, Yoshiharu</creatorcontrib><creatorcontrib>Sasai, Keisuke</creatorcontrib><creatorcontrib>Kinoshita, Hidefumi</creatorcontrib><creatorcontrib>Kamoto, Toshiyuki</creatorcontrib><creatorcontrib>Ogawa, Osamu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mitsumori, Michihide</au><au>Sasaki, Yoshihide</au><au>Mizowaki, Takashi</au><au>Takayama, Kenji</au><au>Nagata, Yasushi</au><au>Hiraoka, Masahiro</au><au>Negoro, Yoshiharu</au><au>Sasai, Keisuke</au><au>Kinoshita, Hidefumi</au><au>Kamoto, Toshiyuki</au><au>Ogawa, Osamu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure</atitle><jtitle>International journal of clinical oncology</jtitle><addtitle>Int J Clin Oncol</addtitle><date>2006-10</date><risdate>2006</risdate><volume>11</volume><issue>5</issue><spage>396</spage><epage>402</epage><pages>396-402</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer. Prostate-specific antigen (PSA) failure-free survival was assessed according to two different definitions, and the appropriateness of each definition is discussed.
Between October 1997 and December 2000, 27 patients with stage III prostate cancer were enrolled in this study. The median pretreatment PSA level was 29 ng/ml (range, 7.4-430 ng/ml). The Gleason score (GS) was 7 or more in 22 patients (81%). All patients received 3 months of NHT with a luteinizing hormone-releasing hormone (LH-RH) analogue, in combination with an antiandrogen (flutamide), given during the first 2 weeks, followed by 70-Gy external-beam radiation therapy (EBRT) in 35 fractions. The initial 46 Gy was given with a four-field technique, while the remainder was given with a dynamic conformal technique. No adjuvant hormonal therapy (AHT) was given.
The median follow-up time was 63 months. PSA levels decreased to the normal range (<4 ng/ml) after irradiation in all but one patient. The 5-year PSA failure-free survival was 34.8% according to the American Society for Therapeutic Radiology and Oncology (ASTRO) definition and it was 43.0% according to the "nadir plus 2" definition. Discordance of the results between the two definitions was seen in two patients. The 5-year overall and cause-specific survivals were 83.0% and 93.3%, respectively. No severe acute or late adverse effects were observed.
Seventy Gy of EBRT following 3 months of NHT produced therapeutic results comparable to those reported in other studies which used long-term AHT. The value of long-term AHT for Japanese men should be tested in a clinical trial.</abstract><cop>Japan</cop><pub>Springer Nature B.V</pub><pmid>17058138</pmid><doi>10.1007/s10147-006-0600-7</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2006-10, Vol.11 (5), p.396-402 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68981003 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - immunology Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Aged Androgen Antagonists - therapeutic use Biomarkers, Tumor - blood Clinical outcomes Clinical trials Cohort Studies Comparative studies Drug Therapy, Combination Flutamide - therapeutic use Gonadotropin-Releasing Hormone - therapeutic use Hormones Humans Japan Male Middle Aged Neoadjuvant Therapy - methods Neoplasm Staging Oncology Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - immunology Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Radiation Radiotherapy Dosage Radiotherapy, Adjuvant Retrospective Studies Survival Analysis |
| title | Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A08%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20radiation%20therapy%20combined%20with%20neoadjuvant%20hormonal%20therapy%20for%20stage%20III%20prostate%20cancer:%20comparison%20of%20two%20different%20definitions%20of%20PSA%20failure&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Mitsumori,%20Michihide&rft.date=2006-10&rft.volume=11&rft.issue=5&rft.spage=396&rft.epage=402&rft.pages=396-402&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-006-0600-7&rft_dat=%3Cproquest_cross%3E68981003%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=203933210&rft_id=info:pmid/17058138&rfr_iscdi=true |